CD47 and telomere syndrome: Anti-CD47 therapy has yielded promising results in early-phase clinical trials among patients with both solid and liquid tumors [170,171], and in vitro experimentation suggests that anti-CD47 therapy induces the expression of proinflammatory cytokines IL2, TNFα, and IFNγ in STS [172].